| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.87 [0.64, 1.18] | | < 1 | | 86% | 3 studies (3/-) | 81.8 % | some concern | not evaluable | moderate | crucial | - |
| deaths (OS) (extension) | 0.62 [0.51, 0.76] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.60 [0.48, 0.74] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 1.16 [0.62, 2.16] | | < 1 | | 96% | 3 studies (3/-) | 32.4 % | some concern | not evaluable | moderate | important | - |
| DCR | 0.86 [0.17, 4.45] | | > 1 | | 96% | 2 studies (2/-) | 43.0 % | low | not evaluable | high | non important | - |
| objective responses (ORR) | 1.32 [0.32, 5.44] | | > 1 | | 73% | 3 studies (3/-) | 65.1 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 1.93 [1.10, 3.38] | | < 1 | | 0% | 1 study (1/-) | 1.1 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 1.10 [0.75, 1.62] | | < 1 | | 0% | 1 study (1/-) | 30.7 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 0.65 [0.37, 1.12] | | < 1 | | 0% | 1 study (1/-) | 94.0 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.93 [0.45, 1.92] | | < 1 | | 0% | 1 study (1/-) | 57.7 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 0.69 [0.29, 1.66] | | < 1 | | 0% | 1 study (1/-) | 79.5 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 0.75 [0.52, 1.10] | | < 1 | | 0% | 1 study (1/-) | 92.6 % | NA | not evaluable | | non important | - |
| SAE (grade 3-4) | 0.92 [0.61, 1.40] | | < 1 | | 0% | 1 study (1/-) | 64.6 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 2.13 [0.96, 4.71] | | < 1 | | 0% | 1 study (1/-) | 3.2 % | NA | not evaluable | | non important | - |
| STRAE (grade 3-4) | 2.67 [0.90, 7.91] | | < 1 | | 0% | 1 study (1/-) | 3.9 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.53 [0.13, 2.10] | | < 1 | | 97% | 3 studies (3/-) | 81.8 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.53 [0.16, 1.73] | | < 1 | | 92% | 3 studies (3/-) | 85.3 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.39 [0.40, 4.81] | | < 1 | | 0% | 3 studies (3/-) | 30.3 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 0.71 [0.40, 1.25] | | < 1 | | 0% | 3 studies (3/-) | 88.4 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 0.65 [0.14, 2.92] | | < 1 | | 0% | 1 study (1/-) | 71.4 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Alopecia TRAE (grade 3-4) | 0.30 [0.03, 3.29] | | < 1 | | 0% | 2 studies (2/-) | 83.5 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.21 [0.02, 2.39] | | < 1 | | 65% | 2 studies (2/-) | 89.3 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.19 [0.02, 1.63] | | < 1 | | 0% | 1 study (1/-) | 93.4 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 0.35 [0.04, 3.29] | | < 1 | | 0% | 2 studies (2/-) | 82.1 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 1.02 [0.15, 7.11] | | < 1 | | 35% | 3 studies (3/-) | 49.2 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 0.94 [0.02, 47.47] | | < 1 | | 0% | 1 study (1/-) | 51.2 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.47 [0.10, 2.15] | | < 1 | | 4% | 3 studies (3/-) | 83.4 % | some concern | not evaluable | moderate | non important | - |
| Fatigue TRAE (grade 3-4) | 0.49 [0.22, 1.09] | | < 1 | | 0% | 3 studies (3/-) | 96.0 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.08 [0.00, 1.40] | | < 1 | | 0% | 1 study (1/-) | 95.7 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 7.60 [0.40, 144.43] | | < 1 | | 0% | 1 study (1/-) | 9.1 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.68 [0.04, 10.84] | | < 1 | | 0% | 2 studies (2/-) | 60.8 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 3.77 [0.17, 84.06] | | < 1 | | 0% | 1 study (1/-) | 20.4 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 4.94 [0.12, 203.36] | | < 1 | | 66% | 2 studies (2/-) | 20.4 % | some concern | not evaluable | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 1.40 [0.36, 5.43] | | < 1 | | 0% | 2 studies (2/-) | 31.6 % | some concern | not evaluable | moderate | non important | - |
| Increased ALT TRAE (grade 3-4) | 0.75 [0.19, 3.00] | | < 1 | | 0% | 2 studies (2/-) | 65.5 % | some concern | not evaluable | moderate | non important | - |
| Increased lipase level TRAE (grade 3-4) | 0.48 [0.04, 5.32] | | < 1 | | 0% | 1 study (1/-) | 72.4 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.95 [0.09, 10.52] | | < 1 | | 0% | 2 studies (2/-) | 51.6 % | some concern | not evaluable | moderate | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.38 [0.07, 2.13] | | < 1 | | 0% | 3 studies (3/-) | 86.3 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.02 [0.00, 0.12] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 0.47 [0.02, 14.02] | | < 1 | | 0% | 1 study (1/-) | 66.7 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.08 [0.00, 1.38] | | < 1 | | 0% | 1 study (1/-) | 95.8 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.04 [0.21, 20.20] | | < 1 | | 0% | 2 studies (2/-) | 27.2 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.98 [0.03, 29.24] | | < 1 | | 0% | 1 study (1/-) | 50.6 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 1.88 [0.06, 56.28] | | < 1 | | 0% | 1 study (1/-) | 36.0 % | NA | not evaluable | | non important | - |
| Thyroiditis TRAE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.24 [0.01, 5.32] | | < 1 | | 0% | 1 study (1/-) | 81.4 % | NA | not evaluable | | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.07 [0.00, 1.17] | | < 1 | | 0% | 1 study (1/-) | 96.6 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 1.14 [0.43, 3.04] | | < 1 | | 0% | 1 study (1/-) | 39.3 % | NA | not evaluable | | non important | - |
| Anaemia AE (grade 3-4) | 0.97 [0.54, 1.75] | | < 1 | | 0% | 1 study (1/-) | 53.7 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 2.48 [0.54, 11.47] | | < 1 | | 0% | 1 study (1/-) | 12.3 % | NA | not evaluable | | non important | - |
| Back pain AE (grade 3-4) | 0.73 [0.12, 4.41] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.98 [0.03, 29.24] | | < 1 | | 0% | 1 study (1/-) | 50.6 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 0.54 [0.20, 1.42] | | < 1 | | 0% | 1 study (1/-) | 89.5 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 1.96 [0.22, 17.71] | | < 1 | | 0% | 1 study (1/-) | 27.5 % | NA | not evaluable | | non important | - |
| Dyspepsia AE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 1.96 [0.09, 43.66] | | < 1 | | 0% | 1 study (1/-) | 33.8 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.29 [0.07, 1.21] | | < 1 | | 0% | 1 study (1/-) | 95.5 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 1.48 [0.47, 4.67] | | < 1 | | 0% | 1 study (1/-) | 25.2 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 1.31 [0.34, 5.00] | | < 1 | | 0% | 1 study (1/-) | 34.7 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.24 [0.02, 2.68] | | < 1 | | 0% | 1 study (1/-) | 87.4 % | NA | not evaluable | | non important | - |
| Peripheral oedema AE (grade 3-4) | 0.98 [0.03, 29.24] | | < 1 | | 0% | 1 study (1/-) | 50.6 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 1.47 [0.15, 14.22] | | < 1 | | 0% | 1 study (1/-) | 37.1 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 0.49 [0.01, 24.66] | | < 1 | | 0% | 1 study (1/-) | 63.8 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.65 [0.14, 2.92] | | < 1 | | 0% | 1 study (1/-) | 71.4 % | NA | not evaluable | | non important | - |
| Weight decreased AE (grade 3-4) | 0.98 [0.03, 29.24] | | < 1 | | 0% | 1 study (1/-) | 50.6 % | NA | not evaluable | | non important | - |
